SAMIL PHARMACEUTICAL CO.,LTD Q3 revenue KRW 51.4 billion, operating loss of KRW 3.19 billion
AI summary · Not investment advice
Samil Pharmaceutical sold KRW 51.4 billion in Q3 and lost KRW 3.19 billion from its main business, versus sales of KRW 51.2 billion and a loss of KRW 5.15 billion a year earlier.
Operating profit · 3 months
KRW -3.2 billion
Key facts
- Revenue (3 months)
- KRW 51.4 billion
- Net income (3 months)
- KRW -6.4 billion
- Period
- Q3 (cumulative Jan 1, 2026 ~ Sep 30, 2026)
- Revenue (prior-year 3 months)
- KRW 51.2 billion
- Revenue (year to date)
- KRW 154.6 billion
- Operating profit (prior-year 3 months)
- KRW -5.2 billion
- Operating profit (year to date)
- KRW -17.9 billion
- Net income (prior-year 3 months)
- KRW -7.9 billion
- Net income (year to date)
- KRW -24.9 billion
Commentary
AI commentary · Not investment advice
What happened
Samil Pharmaceutical filed its quarterly report for the 3rd quarter, on a consolidated basis. Sales for the latest 3 months were KRW 51.42 billion. That is 0.5% above the same period a year earlier and 1.6% above the previous quarter.
In the company's terms
Operating profit (profit from the core business) for the latest 3 months was a loss of KRW 3.19 billion. A year earlier, the 3-month operating loss was KRW 5.15 billion. Net income for the latest 3 months was a loss of KRW 6.40 billion. A year earlier, the 3-month net loss was KRW 7.93 billion.
What changes for shareholders
For the year to date (January 1 to September 30), sales were KRW 154.57 billion. The operating loss was KRW 17.90 billion. The net loss was KRW 24.92 billion.
Comments
No comments yet
Comments from shareholders will appear here.
Ad
Verify your holdings and catch the next disclosure
Verify the stocks you hold and get new disclosures as app alerts.

App design sample
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist
S